Suppr超能文献

甲基化分析显示启动子超甲基化是种罕见的胚系 BRCA1 相关胰腺导管腺癌“二次打击”原因。

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.

出版信息

Mol Diagn Ther. 2022 Nov;26(6):645-653. doi: 10.1007/s40291-022-00614-1. Epub 2022 Sep 30.

Abstract

BACKGROUND AND OBJECTIVE

Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5-6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence on the mechanism of inactivation of the wild-type BRCA1 allele in PDAC tumors with a germline BRCA1 (gBRCA1) pathogenic or likely pathogenic variant (P/LPV). Herein, we examine promotor hypermethylation as a "second hit" mechanism in patients with gBRCA1-PDAC.

METHODS

We evaluated patients with PDAC who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) somatic and germline testing from an institutional database. DNA isolated from tumor tissue and matched normal peripheral blood were sequenced by MSK-IMPACT. In patients with gBRCA1-PDAC, we examined the somatic BRCA1 mutation status and promotor methylation status of the tumor BRCA1 allele via a methylation array analysis. In patients with sufficient remaining DNA, a second methylation analysis by pyrosequencing was performed.

RESULTS

Of 1012 patients with PDAC, 19 (1.9%) were identified to harbor a gBRCA1 P/LPV. Fifteen patients underwent a methylation array and the mean percentage of BRCA1 promotor methylation was 3.62%. In seven patients in whom sufficient DNA was available, subsequent pyrosequencing confirmed an unmethylated BRCA1 promotor. Loss of heterozygosity was detected in 12 of 19 (63%, 95% confidence interval 38-84) patients, demonstrating loss of heterozygosity is the major molecular mechanism of BRCA1 inactivation in PDAC. Two (10.5%) cases had a somatic BRCA1 mutation.

CONCLUSIONS

In patients with gBRCA1-P/LPV-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence.

摘要

背景与目的

胰腺导管腺癌(PDAC)的特征是 5-6%的患者发生 BRCA1/2 的致病性变异。BRCA1/2 的双等位基因缺失可增强对铂类药物和聚(ADP-核糖)聚合酶 1 抑制剂的反应。BRCA1 胚系致病性或可能致病性变异(P/LPV)的 PDAC 肿瘤中,野生型 BRCA1 等位基因失活的机制证据不足。在此,我们研究了 BRCA1 胚系阳性的 PDAC 患者中启动子超甲基化作为“二次打击”机制。

方法

我们从机构数据库中评估了接受 Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets(MSK-IMPACT)体细胞和胚系检测的 PDAC 患者。MSK-IMPACT 通过 MSK-IMPACT 对肿瘤组织和匹配的外周血 DNA 进行测序。在 BRCA1 胚系阳性的 PDAC 患者中,我们通过甲基化阵列分析检测肿瘤 BRCA1 等位基因的体细胞 BRCA1 突变状态和启动子甲基化状态。在有足够剩余 DNA 的患者中,进行了第二次焦磷酸测序甲基化分析。

结果

在 1012 例 PDAC 患者中,发现 19 例(1.9%)存在 BRCA1 P/LPV 胚系阳性。15 例患者进行了甲基化阵列分析,BRCA1 启动子甲基化的平均百分比为 3.62%。在 7 例有足够 DNA 的患者中,后续焦磷酸测序证实 BRCA1 启动子未甲基化。在 19 例患者中,12 例(63%,95%置信区间 38-84)检测到杂合性丢失,表明杂合性丢失是 PDAC 中 BRCA1 失活的主要分子机制。2 例(10.5%)患者存在体细胞 BRCA1 突变。

结论

在 BRCA1 胚系阳性的 PDAC 患者中,杂合性丢失是肿瘤中野生型 BRCA1 等位基因失活的主要机制,BRCA1 启动子甲基化是一种明显罕见的发生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff94/9626413/2caea374c6fd/40291_2022_614_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验